Aligos Therapeutics to Present 10 Abstracts at EASL Congress 2026
Event summary
- 10 abstracts accepted for poster presentations at EASL Congress 2026, May 27–30.
- Focus on chronic hepatitis B, MASH, and hepatitis delta virus therapies.
- Key presentations include data on pevifoscorvir sodium, ALG-170674, and ALG-055009.
- Presenters include academic and industry experts from Hong Kong, France, and the U.S.
The big picture
Aligos Therapeutics is positioning itself as a leader in liver disease therapies, with a focus on chronic hepatitis B and MASH. The EASL Congress presentations provide a platform to validate its pipeline against competitors in a rapidly evolving therapeutic landscape. Success here could accelerate partnerships or licensing deals, particularly for its HBV and MASH candidates.
What we're watching
- Clinical Validation
- Whether the data presented will reinforce pevifoscorvir sodium’s potential as a best-in-class HBV therapy.
- Pipeline Momentum
- The pace at which Aligos can advance its MASH and hepatitis delta virus programs into later-stage trials.
- Investor Sentiment
- How the market reacts to the scientific validation of Aligos’ pipeline at a high-profile liver disease conference.